ERPY Stock Price, News & Analysis

ERPY

Company Description

ERPY (Nasdaq: ERPY) is a publicly traded company.

This page provides a comprehensive overview of ERPY stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

Latest News

View All

October 9, 2023

—

PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains

October 4, 2023

—

PHAXIAM Receives Compliance Notice from Nasdaq

October 3, 2023

—

PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration

September 26, 2023

—

Rapport Financier Semestriel 30 Juin 2023 PHAXIAM

September 21, 2023

—

PHAXIAM Provides Business and Financial Update For the First Half of 2023

September 19, 2023

—

PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target

ERPY has 10 recent news articles. Key topics include stock split, conferences. View all ERPY news →

SEC Filings

View All

No SEC filings available for ERPY.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months